The emerging drug inducible CRISPR/Cas9 systems can be arbitrarily divided into two categories depending on whether at transcription or protein level does chemical control occurs. The first category includes Tet-On/Off system and Cre-dependent system, in which the transcription of Cas9 or sgRNA are subject to chemical control. The second category includes chemically induced proximity (CIP) systems, intein splicing system, 4-Hydroxytamoxifen (4-OHT)-Estrogen Receptor (ER) based nuclear localization systems, allosterically regulated Cas9 (arC9) system, and destabilizing domain (DD) mediated protein degradation systems. Finally, we will discuss the advantages and limitations of each system.
1. Systems of Drug Induction at the Transcription Level
Tet ON/OFF
The Tet system is one of the most wildly used drug inducible transgene expression system. It is based on releasing the Escherichia coli Tet repressor protein (TetR) from its bound tet operator (TetO) sequence upon addition of tetracycline or its derivative dox (doxycycline). Fusion of the VP16 activation domain to TetR results in a transcriptional activator tTA. In the Tet-Off system, dox binds to tTA and triggers its release from the tetO-containing promoter (Ptet), thus switching off its driven transgene. The reverse-tTA (rtTA) is derived from tTA mutant with a reverse activity, which only binds to TetO in the presence of dox. Therefore, in the rtTA based Tet-On system, addition of dox triggers rtTA binding to the Ptet and switches on the target gene. M2rtTA2 is an alternative version of rtTA showing reduced basal expression. The Tet-On 3G protein (TRE3G), which contains 5 amino acid distinctions from M2rtTA2, further increases the sensitively to dox and decreases the background expression when used in combination with optimized tetracycline response element (TRE) repeats, which consists of 7 repeats of the 19 bp TetO sequence (TCCCTATCAGTGATAGAGA) separated by spacers to control Cas9 expression. Further, an optimized M2rtTA2-TRE system was adopted to generate an inducible Cas9 for less background activity in human pluripotent stem cells, named iCRISPR. Replacing Cas9 with dCas9 fused with transcription activation domains such as VP64-P65-Rta (VPR), results in inducible target gene activation.
sgRNA expression can also be regulated by Tet system. sgRNA is driven by the RNA promoter, such as H1. TetR, bound to TetO repeats in between H1 promoter and sgRNA, serves as a block for transcription, thus leading to suppression of sgRNA expression. Dox binding to TetR triggers its release from TetO, thus relieving the suppression of sgRNA expression.
Cre Dependent System
Cre recombinase can efficiently excise DNA fragments flanked by loxP sites in mammalian cells. A loxP-stop-loxP (LSL) cassette can be placed in between a promoter and Cas9 coding sequence. Cre mediated loxP recombination removes stop signal, thus activating Cas9 expression (Fig. 1B). A mouse line containing a LSL-Cas9 cassette knocked in the Rosa26 locus has been generated (ROSA26 is a locus used for constitutive, ubiquitous gene expression in mice. ROSA26 gene itself ubiquitously transcriped over body and over developmental stages but not translated into protein. Thus turn out to be a unessential protein and perfect for knock in experiment. The human version is called AAVS1, AAVS1 (also known as the PPP1R12C locus) on human chromosome 19 is a well-validated “safe harbor” for hosting DNA transgenes with expected function. It has an open chromatin structure and is transcription-competent). Tissue specific expression of Cas9 can be achieved by crossing with mice harboring Cre recombinase driven by tissue specific promoters. In addition, Cre activity can be regulated by fusing with the ligand binding domain (LBD) of the ER (estrogen recptor, in the absence of estrogen, the ER is sequestered by heat shock protein 90 (Hsp90) in the cytoplasm. Upon ligand binding, it disassociates from Hsp90 and translocates to the nucleus, acting as a transcription factor. The LDB of ER has been widely used as a drug inducible tool) or its mutant (Distinct ER mutants with selective affinity to the synthetic 4-OHT over the endogenous β-estradiol were identified, which are critical for reducing undesired background activity), rendering a tamoxifen (has high affinity to modulate ER activity, and its active metabolite version 4-Hydroxytamoxifen, 4OHT, is more frequently used in practice)-dependent Cre action, or by fusing with the LBD of a mutated progesterone receptor which responds to the synthetic steroid RU486 but not endogenous progesterone (progesterone and estrogen is the two most frequent hormone in female).
2, Systems of Drug Induction at the Posttranslational Level
Inducible system at posttranslational level is theoriotically way faster than the previous one in transcriptional level. Some of the following system can reach the response within several hours.
2.1 CIP system
The most widely used CIP system is rapamycin and its derivatives, expanded to the recent developed systems including S-(+)-abscisic acid (ABA)-inducible ABI-PYL1 and gibberellin (GA)-inducible GAI-GID1, both of which were derived from plant hormone signaling pathways.
Rapamycin, an inhibitor of mammalian target of rapamycin, induces heterodimerization of FK506-binding protein (FKBP) and the FKBP-rapamycin-binding domain (FRB). To generate an inducible CRISPR/Cas9 system, Bernd Zetche et al. splitted Streptococcus pyogenes Cas9 (SpCas9) into two parts, Cas9(N) and Cas9(C) based on information from its crystal structure, and fused them with FRB and FKBP, respectively. The two split parts can be reconstituted to the full and functional Cas9 in the presence of rapamycin (Fig. 2A, upper panel). However, the Cas9 background activity was high due to auto-assembly in the absence of rapamycin. To damp the background activity, the authors compartmentalized the two split partners by fusing a nuclear export sequence (NES) to Cas9(N)-FRB fragment and two nuclear localization sequences (NLS) to Cas9(C)-FKBP. In addition, Bernd Zetche et al. applied this strategy to dCas9 and fused VP64 activation domain to one split fragment to achieve rapamycin inducible transcription activation.
Similarly, ABA induces heterodimerization of ABI1 and PYL1, which are fused with dCas9 and activation domains (ADs) respectively. GA, on the other hand, introduces dimerizaiton of GAI and GID1. Importantly, ABA- and GA-inducible systems were demonstrated to be reversible and dose responsive.
2.2 Intein splicing
Inteins are similar to self-splicing introns, however, they are transcribed and translated together with their host proteins. After translation, Inteins catalyze auto-excitation of themselves and concomitantly join the flanking peptides without perturbing their biological function.
The 4-OHT-responsive intein were created by insertion of the human LBD of ER into the M. tuberculosis RecA intein, and an evolved clone, 37R3–2 with higher splicing efficiency were identified. To generate an optimally recovered Cas9 upon splicing, 37R3–2 were inserted in Cas9 at specific sites (S219 or C574) after testing 15 candidate sites. The authors further demonstrated that this conditionally active Cas9 induced a comparable genome editing efficiency as wild-type Cas9 at several endogenous genomic loci. However, a major limitation of the intein-based system is that it is irreversible.
2.3 Systems based on 4-OHT driven ER nuclear translocation
As the figure suggested, at the absence of 4OHT, ERT2 is captured by HSP90 at cytoplasm. Since Cas9 is designed to binded to ERT2, Cas9 can not be transported to nuclus and inactivated. When 4OHT is applied, HSP90 is replaced by 4OHT and CAS9-ERT2 complex can be transported into nuclus thus be activated.
2.4 Allosterically regulated Cas9
In sum, a confirmation changed is designed to make sure, when 4OHT is applied, ER-LBD change its confirmation and thus change the confirmation of Cas9 to make it be activated.
2.5 Destabilized domains (DDs) controlled CAS9 systems
DD is an engineered unstable LBD that degraded in the absence of ligand. When DD fusion to a protein of interest, the stability of the fusion protein will be under small molecule control. In the absence of small molecule ligand, DD directs the fusion protein to proteosome dependant degradation. Ligand binding to DD shields the fusion protein from degradation. Several ligand-DD pairs have been generated through mutant library screen, including Shield1-FKBP12 mutant [[75], [76]], trimethoprim (TMP)-Escherichia coli dihydrofolate reductase (DHFR) mutant [[77], [78], [79], [80], [81]] and CMP8/4-OHT-Estrogen receptor destabilized domain (ER50 DD).
These info are extracted from this paper followed.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709367/